Aug 5, 2026 08:30AM
Aug 5, 2026 08:30AM
Jul 21, 2026 04:30PM
May 21, 2026 07:30AM
May 15, 2026 04:00PM
May 13, 2026 04:10PM
May 13, 2026 04:10PM Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
Apr 17, 2026 04:00PM
Apr 17, 2026 04:00PM
Apr 15, 2026 04:05PM
Mar 19, 2026 07:21AM
Mar 17, 2026 05:54PM
Mar 2, 2026 03:39PM
Feb 24, 2026 08:00AM Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Feb 23, 2026 08:00AM
Feb 18, 2026 08:00AM
Feb 17, 2026 10:48AM
Jan 23, 2026 08:13AM
Jan 23, 2026 08:11AM
Jan 8, 2026 07:32AM
Jan 8, 2026 07:30AM Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled
Jan 6, 2026 07:30AM
Jan 6, 2026 07:30AM
Dec 17, 2025 09:34AM
Dec 17, 2025 09:34AM
Dec 17, 2025 07:30AM
Dec 17, 2025 07:30AM
Nov 13, 2025 04:10PM Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
Oct 22, 2025 04:27PM
Oct 22, 2025 04:15PM
Oct 1, 2025 04:30PM
Aug 13, 2025 04:15PM
May 15, 2025 07:26AM
May 14, 2025 04:10PM
Apr 25, 2025 08:00AM Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
Apr 7, 2025 04:05PM
Apr 7, 2025 04:05PM
Mar 27, 2025 05:44PM
Mar 19, 2025 08:00AM
Mar 19, 2025 08:00AM
Feb 5, 2025 08:00AM
Feb 5, 2025 08:00AM Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
Nov 13, 2024 07:00AM
Oct 17, 2024 08:00AM
Oct 16, 2024 04:00PM
Oct 11, 2024 08:03AM
Oct 11, 2024 08:00AM
Sep 16, 2024 06:46AM
Sep 14, 2024 03:10AM Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on
Sep 10, 2024 08:00AM

327,801 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All